The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Feasibility of vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy for adult rhabdomyosarcoma (RMS) with regard to dose intensity (DI).
Y. Kojima
No relevant relationships to disclose
K. Hashimoto
No relevant relationships to disclose
M. Ando
No relevant relationships to disclose
K. Yonemori
No relevant relationships to disclose
H. Yamamoto
No relevant relationships to disclose
M. Kodaira
No relevant relationships to disclose
M. Yunokawa
No relevant relationships to disclose
C. Shimizu
No relevant relationships to disclose
K. Tamura
No relevant relationships to disclose
N. Katsumata
No relevant relationships to disclose
A. Makimoto
No relevant relationships to disclose
Y. Fujiwara
No relevant relationships to disclose